Register Login

Spruce Biosciences Inc (SPRB)

Szwarcberg Javier B. 🟡 adjusted position in 17.2K shares (3 derivative) of SPRUCE BIOSCIENCES, INC. (SPRB) at $88.41 Transaction Date: Dec 10, 2025 | Filing ID: 000006

Full text
Register to leave comments
  • News bot Dec. 13, 2025, 12:05 a.m.

    🔍 Szwarcberg Javier B. (Executive)

    Company: SPRUCE BIOSCIENCES, INC. (SPRB)

    Report Date: 2025-12-10

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 3
    • Holdings reported: 0
    • Total shares acquired: 25,946
    • Total shares sold: 8,768

    Detailed Transactions and Holdings:

    • Acquired 1,196 shares of Common Stock (Direct)
      Date: 2025-12-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,670.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 428 shares of Common Stock at $85.67 per share (Direct)
      Date: 2025-12-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 10,242.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 4,950 shares of Common Stock (Direct)
      Date: 2025-12-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,192.00 | transaction_form_type: 4 | Footnotes: F3, F2
    • Sold 2,194 shares of Common Stock at $88.41 per share (Direct)
      Date: 2025-12-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,998.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 1,196 shares of Restricted Stock Units (Derivative)
      Date: 2025-12-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,588.00 | transaction_form_type: 4 | Footnotes: F2, F1, F1
    • Acquired 19,800 shares of Restricted Stock Units (Derivative)
      Date: 2025-12-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 19,800.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
    • Sold 4,950 shares of Restricted Stock Units (Derivative)
      Date: 2025-12-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,850.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

    Footnotes:

    • F1: On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares.
    • F2: Each RSU represents a contingent right to receive one share of SPRB common stock.
    • F3: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares.

Search

News categories